380 related articles for article (PubMed ID: 36043445)
1. Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma.
Xie Y; Yan F; Wang X; Yu L; Yan H; Pu Q; Li W; Yang Z
Cancer Med; 2023 Feb; 12(3):3237-3259. PubMed ID: 36043445
[TBL] [Abstract][Full Text] [Related]
2. Yangyin Fuzheng Jiedu Prescription exerts anti-tumor immunity in hepatocellular carcinoma by alleviating exhausted T cells.
Yan F; Wang X; Xie Y; Liu X; Yu L; Wang P; Li T; Wang S; Li W; Yang Z
Phytomedicine; 2021 Oct; 91():153722. PubMed ID: 34488188
[TBL] [Abstract][Full Text] [Related]
3. Predicting the mechanism of action of YQYYJD prescription in the treatment of non-small cell lung cancer using transcriptomics analysis.
Yin Y; Wang Y; Wang C; Zhang Y; Qi A; Song J; Xu L; Yang W; Jiao L
J Ethnopharmacol; 2024 May; 326():117984. PubMed ID: 38428661
[TBL] [Abstract][Full Text] [Related]
4. Molecular targets of Yangyin Fuzheng Jiedu Prescription in the treatment of hepatocellular carcinoma based on network pharmacology analysis.
Yan F; Feng M; Wang X; Wang P; Xie Y; Liu X; Li W; Yang Z
Cancer Cell Int; 2020 Nov; 20(1):540. PubMed ID: 33292207
[TBL] [Abstract][Full Text] [Related]
5. A network pharmacology approach and experimental validation to investigate the anticancer mechanism and potential active targets of ethanol extract of Wei-Tong-Xin against colorectal cancer through induction of apoptosis via PI3K/AKT signaling pathway.
Lin F; Zhang G; Yang X; Wang M; Wang R; Wan M; Wang J; Wu B; Yan T; Jia Y
J Ethnopharmacol; 2023 Mar; 303():115933. PubMed ID: 36403742
[TBL] [Abstract][Full Text] [Related]
6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
7. Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment.
Li H; You J; Wei Y; Zheng L; Yang J; Xu J; Li Y; Li Z; Yang X; Yi C
Phytomedicine; 2024 Jan; 123():155189. PubMed ID: 37984124
[TBL] [Abstract][Full Text] [Related]
8. A network pharmacology and bioinformatics exploration of the possible molecular mechanisms of Fuzheng Xiaoliu Granule for the treatment of hepatocellular carcinoma.
Fan T; Chen X; Yang F; Li Y; Gao Q; Li S; Chen X; Chen X
J Clin Transl Res; 2023 Jun; 9(3):182-194. PubMed ID: 37275579
[TBL] [Abstract][Full Text] [Related]
9. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
10. [Blaps rynchopetera affects proliferation, migration, and invasion of non-small cell lung cancer: a study based on network pharmacology and in vivo and in vitro experiments].
Li XY; Ma K; Yan JN; You FC; Ma L
Zhongguo Zhong Yao Za Zhi; 2023 Jul; 48(13):3576-3588. PubMed ID: 37474991
[TBL] [Abstract][Full Text] [Related]
11. In Silico and In Vitro Studies on the Mechanisms of Chinese Medicine Formula (Yiqi Jianpi Jiedu Formula) in the Treatment of Hepatocellular Carcinoma.
Wu Z; Kang J; Tan W; Wei C; He L; Jiang X; Peng L
Comput Math Methods Med; 2022; 2022():8669993. PubMed ID: 36345477
[TBL] [Abstract][Full Text] [Related]
12. Lobelia chinensis Lour inhibits the progression of hepatocellular carcinoma via the regulation of the PTEN/AKT signaling pathway in vivo and in vitro.
Luo J; Chen QX; Li P; Yu H; Yu L; Lu JL; Yin HZ; Huang BJ; Zhang SJ
J Ethnopharmacol; 2024 Jan; 318(Pt A):116886. PubMed ID: 37429502
[TBL] [Abstract][Full Text] [Related]
13. Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses.
Zhang XS; Zhou HC; Wei P; Chen L; Ma WH; Ding L; Liang SC; Chen BD
World J Gastrointest Oncol; 2023 Dec; 15(12):2138-2149. PubMed ID: 38173440
[TBL] [Abstract][Full Text] [Related]
14. PD-1
Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z
Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814
[TBL] [Abstract][Full Text] [Related]
15. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
[TBL] [Abstract][Full Text] [Related]
16. A Strategy based on Bioinformatics and Machine Learning Algorithms Reveals Potential Mechanisms of Shelian Capsule against Hepatocellular Carcinoma.
Zhou X; Tan F; Zhang S; Wang A; Zhang T
Curr Pharm Des; 2024; 30(5):377-405. PubMed ID: 38310567
[TBL] [Abstract][Full Text] [Related]
17. Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8
Zhang H; Zhang Y; Dong J; Zuo S; Meng G; Wu J; Wei J
Cell Oncol (Dordr); 2021 Dec; 44(6):1243-1255. PubMed ID: 34491549
[TBL] [Abstract][Full Text] [Related]
18. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
[TBL] [Abstract][Full Text] [Related]
19. Investigating the molecular mechanism of Qizhu anticancer prescription in inhibiting hepatocellular carcinoma based on high-resolution mass spectrometry and network pharmacology.
Sun J; Ma M; Zhong X; Li J; Yi J; Zhang R; Liu X; Peng L; Sun X; Feng W; Hu R; Huang Q; Lv M; Fan K; Zhou X
J Ethnopharmacol; 2024 Jun; 328():117985. PubMed ID: 38417600
[TBL] [Abstract][Full Text] [Related]
20. Blockade of T-cell receptor with Ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBV-related HCC in mice.
Wu Y; Hao X; Wei H; Sun R; Chen Y; Tian Z
Hepatology; 2023 Mar; 77(3):965-981. PubMed ID: 35938354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
